PYRIDOXINE DIPALMITATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C38H67NO5
Molecular Weight	617.9423
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCCCCCCCC(=O)OC1=CN=C(C)C(O)=C1OC(=O)CCCCCCCCCCCCCCC

InChI

InChIKey=XQPZOTDPIYWJQZ-UHFFFAOYSA-N

InChI=1S/C38H67NO5/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-35(40)43-34-32-39-33(3)37(42)38(34)44-36(41)31-29-27-25-23-21-19-17-15-13-11-9-7-5-2/h32,42H,4-31H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C38H67NO5
Molecular Weight	617.9423
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00165
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/pyridoxine-hydrochloride-injection.html

Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Vitamin B6 (pyridoxine) is a water-soluble vitamin used in the prophylaxis and treatment of vitamin B6 deficiency and peripheral neuropathy in those receiving isoniazid (isonicotinic acid hydrazide, INH). Vitamin B6 has been found to lower systolic and diastolic blood pressure in a small group of subjects with essential hypertension. Hypertension is another risk factor for atherosclerosis and coronary heart disease. Another study showed pyridoxine hydrochloride to inhibit ADP- or epinephrine-induced platelet aggregation and to lower total cholesterol levels and increase HDL-cholesterol levels, again in a small group of subjects. Vitamin B6, in the form of pyridoxal 5'-phosphate, was found to protect vascular endothelial cells in culture from injury by activated platelets. Endothelial injury and dysfunction are critical initiating events in the pathogenesis of atherosclerosis. Human studies have demonstrated that vitamin B6 deficiency affects cellular and humoral responses of the immune system. Vitamin B6 deficiency results in altered lymphocyte differentiation and maturation, reduced delayed-type hypersensitivity (DTH) responses, impaired antibody production, decreased lymphocyte proliferation and decreased interleukin (IL)-2 production, among other immunologic activities. Used for the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Oxidative Stress 162 Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21944860	Inhibitor 8504		8.3 mM [Ki]
Alpha-1-antichymotrypsin 3 Target ID: CHEMBL5960 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21462331	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
West syndrome 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11409832https://www.ncbi.nlm.nih.gov/pubmed/14738417http://medicaljournal.blogspot.com/2007/05/infantile-spasm-west-syndrome_13.html	Primary	Approved 8583	Unknown Approved Use Unknown
Pyridoxine-dependent epilepsy 3 Sources: https://rarediseases.org/rare-diseases/pyridoxine-dependent-epilepsy/https://www.ncbi.nlm.nih.gov/pubmed/20554659	Primary	Approved 8583	Unknown Approved Use Unknown
Pyridoxine deficiency 3 Sources: https://www.drugs.com/pro/pyridoxine-hydrochloride-injection.html	Primary	Approved 8583	PYRIDOXINE HYDROCHLORIDE Approved Use Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. Launch Date 1972

C_max

Value	Dose	Co-administered	Analyte	Population
372.7 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2183.2 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PYRIDOXAL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
892.9 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PYRIDOXAL PHOSPHATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1750.3 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		4-PYRIDOXIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
47.1 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
58.9 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
30.1 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL PHOSPHATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
48.2 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
189.6 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
85.9 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL PHOSPHATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
38.9 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
12.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT
62 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
33.1 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT
27.4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL PHOSPHATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
30.2 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL PHOSPHATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT

AUC

Value	Dose	Co-administered	Analyte	Population
2008.9 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
18603.4 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PYRIDOXAL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
19420.2 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PYRIDOXAL PHOSPHATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
18543.1 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7988052/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		4-PYRIDOXIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
42.5 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
233.6 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
1076.2 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL PHOSPHATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
80 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
1511.3 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
1742.3 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL PHOSPHATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
35.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
27 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT
244 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
249.2 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT
1021.7 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL PHOSPHATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
1064.6 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL PHOSPHATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
1.2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT
8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
12.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	PYRIDOXAL blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: HIGH-FAT

Doses

Dose	Population	Adverse events
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000MedR.pdf	pregnant, mean age 26 years Health Status: pregnant Age Group: mean age 26 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000MedR.pdf	Disc. AE: Somnolence, Syncope... AEs leading to discontinuation/dose reduction: Somnolence (1.5%) Syncope (0.7%) Dizziness (0.7%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000MedR.pdf
117 mg multiple, oral Studied dose Dose: 117 mg Route: oral Route: multiple Dose: 117 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3630649/	unhealthy, mean age 41.5 years Health Status: unhealthy Age Group: mean age 41.5 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3630649/	Disc. AE: Paraesthesia, Muscle weakness... AEs leading to discontinuation/dose reduction: Paraesthesia (34%) Muscle weakness (19.2%) Numbness (12.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/3630649/
175 mg multiple, oral Studied dose Dose: 175 mg Route: oral Route: multiple Dose: 175 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/	unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/	Disc. AE: Depression, Headache... AEs leading to discontinuation/dose reduction: Depression (79%) Headache (48%) Tiredness (59%) Irritability (38%) Neuropathy (40%) Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/

AEs

AE	Significance	Dose	Population
Dizziness	0.7% Disc. AE	10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000MedR.pdf	pregnant, mean age 26 years Health Status: pregnant Age Group: mean age 26 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000MedR.pdf
Syncope	0.7% Disc. AE	10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000MedR.pdf	pregnant, mean age 26 years Health Status: pregnant Age Group: mean age 26 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000MedR.pdf
Somnolence	1.5% Disc. AE	10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000MedR.pdf	pregnant, mean age 26 years Health Status: pregnant Age Group: mean age 26 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000MedR.pdf
Numbness	12.2% Disc. AE	117 mg multiple, oral Studied dose Dose: 117 mg Route: oral Route: multiple Dose: 117 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3630649/	unhealthy, mean age 41.5 years Health Status: unhealthy Age Group: mean age 41.5 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3630649/
Muscle weakness	19.2% Disc. AE	117 mg multiple, oral Studied dose Dose: 117 mg Route: oral Route: multiple Dose: 117 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3630649/	unhealthy, mean age 41.5 years Health Status: unhealthy Age Group: mean age 41.5 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3630649/
Paraesthesia	34% Disc. AE	117 mg multiple, oral Studied dose Dose: 117 mg Route: oral Route: multiple Dose: 117 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3630649/	unhealthy, mean age 41.5 years Health Status: unhealthy Age Group: mean age 41.5 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3630649/
Irritability	38% Disc. AE	175 mg multiple, oral Studied dose Dose: 175 mg Route: oral Route: multiple Dose: 175 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/	unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/
Neuropathy	40% Disc. AE	175 mg multiple, oral Studied dose Dose: 175 mg Route: oral Route: multiple Dose: 175 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/	unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/
Headache	48% Disc. AE	175 mg multiple, oral Studied dose Dose: 175 mg Route: oral Route: multiple Dose: 175 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/	unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/
Tiredness	59% Disc. AE	175 mg multiple, oral Studied dose Dose: 175 mg Route: oral Route: multiple Dose: 175 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/	unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/
Depression	79% Disc. AE	175 mg multiple, oral Studied dose Dose: 175 mg Route: oral Route: multiple Dose: 175 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/	unhealthy, mean age 42 years Health Status: unhealthy Age Group: mean age 42 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/2860378/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
		CYP1A1 151

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A1 272	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/19637937/ Page: 12.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:16709	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16709
ChemicalBook	CB0197939	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0197939
ChemicalBook	CB8197940	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8197940
eMolecules	593675	https://www.emolecules.com/cgi-bin/more?vid=593675
MolPort	MolPort-002-319-991	https://www.molport.com/shop/molecule-link/MolPort-002-319-991
ZINC	ZINC000000049154	http://zinc15.docking.org/substances/ZINC000000049154

PubMed

Title	Date	PubMed
Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.	2001-09	11500187
Experimental model of pyridoxine (B6) deficiency-induced neuropathy.	2001-08	11506323
The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy.	2001-08	11504271
Pyridoxine-induced neuropathy in rats: a sensory neuropathy that responds to 4-methylcatechol.	2001-08	11493027
Homocysteine levels in patients treated with lipid apheresis: effect of a vitamin therapy.	2001-08	11473567
[Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients].	2001-07-24	11464650
X-ray structure of Escherichia coli pyridoxine 5'-phosphate oxidase complexed with pyridoxal 5'-phosphate at 2.0 A resolution.	2001-07-20	11453690
Analyzing counts, durations, and recurrences in clinical trials.	2001-07-19	11459443
Continuous combined hormone replacement therapy with oral 17beta-estradiol and norethisterone acetate improves homocysteine metabolism in postmenopausal women.	2001-07-13	11449082
Thiamine, riboflavin, pyridoxine, and vitamin C status in premature infants receiving parenteral and enteral nutrition.	2001-07	11479410
Does lowering plasma homocysteine reduce vascular disease risk?	2001-07	11475450
A population study of the influence of beer consumption on folate and homocysteine concentrations.	2001-07	11464234
Homocysteine--a treatable risk factor for allograft vascular disease after heart transplantation?	2001-07	11448801
Intravenous pyridoxine-induced metabolic acidosis.	2001-07	11423814
Multi-task flow system for potentiometric analysis: its application to the determination of vitamin B6 in pharmaceuticals.	2001-07	11377053
[Homocysteine metabolism and risk of cardiovascular diseases: importance of the nutritional status on folic acid, vitamins B6 and B12].	2001-06-26	11421110
Effects of short-term dietary administration of marginal levels of vitamin B(6)and fish oil on lipid composition and antioxidant defences in rat tissues.	2001-06-22	11418022
Application of liquid chromatography to the simultaneous determination of acetylsalicylic acid, caffeine, codeine, paracetamol, pyridoxine, and thiamine in pharmaceutical preparations.	2001-06-22	11417630
Risk and uncertainty.	2001-06-21	11418834
A general family of distributions for longitudinal dependence with special reference to event histories.	2001-06-15	11391692
Light-dependent generation of reactive oxygen species in cell culture media.	2001-06-15	11390187
Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels.	2001-06-12	11401933
Low dietary folate intake is associated with an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk Factor Study.	2001-06-05	11390336
Pyridoxine-dependent and pyridoxine-responsive seizures.	2001-06	11409832
Pyridoxine-dependent seizures responding to extremely low-dose pyridoxine.	2001-06	11409831
Vitamin B1 and B6 retention in milk after continuous-flow microwave and conventional heating at high temperatures.	2001-06	11403146
Blood determinations of S-adenosylmethionine, S-adenosylhomocysteine, and homocysteine: correlations with diet.	2001-06	11401915
Sensitivity to meat protein intake and hyperoxaluria in idiopathic calcium stone formers.	2001-06	11380831
Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations.	2001-06	11380830
Simultaneous determination of thiamine and pyridoxine in pharmaceuticals by using a single flow-through biparameter sensor.	2001-06	11377043
Influence of vitamin-optimized plasma homocysteine cutoff values on the prevalence of hyperhomocysteinemia in healthy adults.	2001-06	11375284
Impaired heme binding and aggregation of mutant cystathionine beta-synthase subunits in homocystinuria.	2001-06	11359213
Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project.	2001-05-29	11382721
Disposition of homocysteine in subjects heterozygous for homocystinuria due to cystathionine beta-synthase deficiency: relationship between genotype and phenotype.	2001-05-01	11343305
[Behavioral disorders after treatment with isoniazid].	2001-05	11475027
[Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].	2001-05	11419053
Homocysteine--an innocent bystander in vascular disease?	2001-05	11350100
[Determination of 4-O-methylpyridoxine (MPN) by HPLC with diode-array detector].	2001-04	11505497
Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1.	2001-04	11386466
Do breastfed infants need supplemental vitamins?	2001-04	11339161
Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate.	2001-03	11426667
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.	2001-02-01	11462975
[Healing with vitamins].	2001-02	11345605
[Acute isoniazid poisoning presenting convulsion and liver dysfunction].	2001-01	11381464
[Metadoxyl in combined treatment of alcohol damage to the liver].	2001	11496744
Nutritional disorders among workers in North China during national turmoil.	2001	11464001
Clinical and institutional aspects of antidote therapy in Russia.	2001	11450355
Drug treatment for tuberculosis during pregnancy: safety considerations.	2001	11444726
[Evaluation of vitamin B6 and calcium pantothenate effectiveness on hair growth from clinical and trichographic aspects for treatment of diffuse alopecia in women].	2001	11344694
[Effects of biologically active supplements on the antioxidant and vitamin status of patients with hypertension and ischemic heart disease].	2001	11338339

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Dietary Supplement Pyridoxine Deficiency: 10 to 25 mg/day orally, IM, or IV for 3 weeks followed by 2 to 5 mg/day from a multivitamin product. Usual Adult Dose for Anemia Sideroblastic, hereditary: 200 to 600 mg orally daily. If adequate response obtained, dose may be decreased to 30 to 50 mg orally daily.

Route of Administration: Other

In Vitro Use Guide

Pyridoxine (5 mmol/l) caused complete inhibition of microvessel outgrowth in rat aortic rings

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:24:36 GMT 2025` Edited by `admin` on `Mon Mar 31 21:24:36 GMT 2025`
Record UNII	HB49XCT029
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PYRIDOXINE DIPALMITATE

Official Name

English

HEXADECANOIC ACID, (5-HYDROXY-6-METHYL-3,4-PYRIDINEDIYL)BIS(METHYLENE) ESTER

Preferred Name

English

5-HYDROXY-6-METHYL-3,4-PYRIDINEDIMETHANOL DIPALMITATE

Systematic Name

English

VITAMIN B6 DIPALMITATE

Common Name

English

Pyridoxine dipalmitate [WHO-DD]

Common Name

English

PALMITIC ACID, DIESTER WITH PYRIDOXOL

Common Name

English

Code System Code Type Description

RXCUI

1314231